¼¼°èÀÇ ¿ÜÀ½ºÎÅë Ä¡·á ½ÃÀå º¸°í¼­(2025³â)
Vulvodynia Treatment Global Market Report 2025
»óǰÄÚµå : 1695282
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,242,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,023,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,803,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¿ÜÀ½ºÎÅë Ä¡·á ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö ¿¬Æò±Õ 6.5%ÀÇ CAGR·Î 74¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº °³ÀÎÈ­µÈ ÀÇ·á Á¢±Ù¹ý, ½É¸® Ä¡·áÀû °³ÀÔÀÇ ÅëÇÕ, »õ·Î¿î Ä¡·á¹ý ¿¬±¸, ȯÀÚ ±ÇÇÑ ºÎ¿© ¹× ±³À°, ¼¼°è º¸°Ç ÀÌ´Ï¼ÅÆ¼ºê¿¡ ±âÀÎÇÕ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Ä¡·á Á¢±Ù¹ýÀÇ ¹ßÀü, ¸ÂÃãÇü ÀÇ·á ¹× Ç¥Àû Ä¡·á, ½É¸® Áö¿øÀÇ ÅëÇÕ, »õ·Î¿î Ä¡·á Ç¥Àû ¿¬±¸, ÀÓ»ó ¿¬±¸¿¡¼­ÀÇ Çù·ÂÀû Á¢±Ù µîÀÌ ÀÖ½À´Ï´Ù.

¿ÜÀ½ºÎÅë Ä¡·á ½ÃÀåÀº ºñ´¢»ý½Ä±â ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. »ý½Ä±â ¹× ºñ´¢±â °èÅë¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ´ç´¢º´, °íÇ÷¾Ð µîÀÇ Áúȯ°ú ¿¬°üµÇ´Â °æ¿ì°¡ ¸¹Àº ºñ´¢±â ÁúȯÀº Áõ°¡ Ãß¼¼ÀÔ´Ï´Ù. ¹Ì±¹¿¡¼­¸¸ 2022³â ¾à 444,660¸íÀÌ ºñ´¢±â¾ÏÀ¸·Î »õ·Î Áø´Ü¹Þ°í ¾à 67,330¸íÀÌ »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³­¼Ò¾ÏÀ» Æ÷ÇÔÇÑ ÀÌ·¯ÇÑ ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¿ÜÀ½ºÎÅë Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. ¿ÜÀ½ºÎÅë Ä¡·á´Â ÁÖ·Î ¿©¼ºÀÇ ´Ù¾çÇÑ ºñ´¢±â°è ÁúȯÀ» ´ë»óÀ¸·Î Çϸç, ÅëÁõ ¿ÏÈ­, Áõ»ó ¿ÏÈ­, ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

¶ÇÇÑ, ¿ÜÀ½ºÎÅë Ä¡·á ½ÃÀåÀº ¿©¼ºÀÇ ºÒ¾ÈÁõ Áõ°¡·Î ÀÎÇØ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±äÀå, ºÒ¾ÈÇÑ »ý°¢, ½ÅüÀû º¯È­¸¦ Ư¡À¸·Î ÇÏ´Â ºÒ¾ÈÀº ¿©¼ºÀÇ ¿ÜÀ½ºÎÅë¿¡ ´ëÇÑ °¨¼ö¼ºÀÌ ³ôÀº °Í°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ºÒ¾È ¼öÁØÀÌ ³ôÀº »ç¶÷µéÀº ¿ÜÀ½ºÎ¿¡ 4 ¹è ´õ ½±°Ô ¿ÜÀ½ºÎÅëÀÌ ¹ß»ýÇϱ⠽±°í, ¿ÜÀ½ºÎÀÇ ¹ß´ÞÀº Á¾Á¾ ºÒ¾È°ú ¿ì¿ïÁõÀ» ¾ÇÈ­½Ãŵ´Ï´Ù. Á¤½Å°Ç°­ Àç´ÜÀÇ ÃÖ±Ù µ¥ÀÌÅÍ¿¡ µû¸£¸é ³²¼ºº¸´Ù ¿©¼ºÀÇ ºÒ¾È ¼öÁØÀÌ ´«¿¡ ¶ç°Ô Áõ°¡ÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿©¼ºÀÇ ºÒ¾È°¨ ±ÞÁõÀº ¿ÜÀ½ºÎÅë Ä¡·á ½ÃÀåÀÇ ÃËÁø¿äÀÎÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Vulvodynia treatment encompasses medical and therapeutic approaches aimed at managing and alleviating the symptoms of vulvodynia-a chronic pain condition characterized by unexplained and persistent discomfort or pain in the vulvar area of the female genitalia. The goal of treatment is to relieve pain, improve a woman's quality of life, and help her resume normal activities, including sexual intercourse.

The main types of drugs used in vulvodynia treatment include anticonvulsants, tricyclic antidepressants, local anesthetics, antimicrobials, hormone creams, and nerve blocks. Anticonvulsants, also known as antiepileptic drugs (AEDs), form a class of pharmaceuticals that normalize the way nerve impulses travel along nerve cells, helping prevent or treat seizures. These drugs can be administered orally, topically, or through other methods and are distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The vulvodynia treatment market research report is one of a series of new reports from The Business Research Company that provides vulvodynia treatment market statistics, including vulvodynia treatment industry global market size, regional shares, competitors with a vulvodynia treatment market share, detailed vulvodynia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the vulvodynia treatment industry. This vulvodynia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vulvodynia treatment market size has grown strongly in recent years. It will grow from $5.41 billion in 2024 to $5.79 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increasing awareness and diagnosis, changing societal attitudes, gynecological advances, patient advocacy and support groups.

The vulvodynia treatment market size is expected to see strong growth in the next few years. It will grow to $7.45 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to personalized medicine approaches, integration of psychotherapeutic interventions, research on novel therapies, patient empowerment and education, global health initiatives. Major trends in the forecast period include advancements in therapeutic approaches, personalized medicine and targeted therapies, integration of psychological support, research into novel therapeutic targets, collaborative approaches in clinical research.

The vulvodynia treatment market is anticipated to experience growth, driven by the rise in genitourinary diseases. Genitourinary diseases, affecting the reproductive and urinary systems and often associated with conditions such as diabetes or high blood pressure, have been on the increase. In the US alone, it was projected that around 444,660 individuals would receive new diagnoses of genitourinary cancers in 2022, with approximately 67,330 recorded deaths. The escalating prevalence of such diseases, including ovarian cancers, is a significant factor propelling the growth of the vulvodynia treatment market. Vulvodynia treatment primarily targets various genitourinary diseases in females, aiming to alleviate pain, reduce symptoms, and enhance patients' quality of life.

The vulvodynia treatment market is also expected to see growth due to the increasing incidence of anxiety in women. Anxiety, characterized by tension, worried thoughts, and physical changes, is linked to a higher susceptibility to vulvodynia in women. Those with high anxiety levels are four times more prone to vulvodynia, and the development of vulvodynia often exacerbates anxiety and depression. Recent data from the Mental Health Foundation indicates a notable increase in anxiety levels among women compared to men. This surge in anxiety among women is identified as a driving factor for the vulvodynia treatment market.

Leading companies in the vulvodynia treatment market are addressing these challenges by developing innovative drugs and obtaining regulatory approvals for treating vulvodynia. Oteseconazole is one such innovative drug developed by Mycovia Pharmaceuticals Inc. This azole antifungal, available in capsule form under the name Vivjoa, received approval from the U.S. Food and Drug Administration (FDA) in July 2022. Vivjoa is prescribed to reduce the risk of recurrent vulvovaginal candidiasis (RVVC) by inhibiting yeast cell growth. The development and approval of such drugs demonstrate a commitment to providing effective and targeted treatments for chronic pain conditions associated with vulvodynia.

In August 2022, Upsher-Smith Laboratories LLC collaborated with Emphascience, Inc., aiming to expand its portfolio with high-touch generic products that address unmet patient needs. Emphascience Inc., specializing in developing novel treatments for chronic pain, entered into this partnership to bring ES-001, a potential solution, to market.

Major companies operating in the vulvodynia treatment market report are Pfizer Inc., Johnson and Johnson Pvt. Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Mylan N.V., Astellas Pharma Inc., Viatris Inc., Cipla Inc., Hikma Pharmaceuticals PLC, Endo International Inc., Amneal Pharmaceuticals Inc., Stada Arzneimittel AG, Glenmark Pharmaceuticals Inc., Alkem Laboratories Limited, Cadila Pharmaceuticals Ltd., Taro Pharmaceutical Industries Ltd., Upsher-Smith Laboratories LLC, Noven Pharmaceuticals Inc., National Vulvodynia Association, Zydus Lifesciences Ltd., Depomed Inc.

North America was the largest region in the vulvodynia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vulvodynia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the vulvodynia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The vulvodynia treatment market consists of revenues earned by entities by providing services such as pelvic floor physical therapy, cognitive behavioral therapy, acupuncture, exposure therapy, supportive psychotherapy, relaxation therapies, group therapy, stress management, and self-care practices. The market value includes the value of related goods sold by the service provider or included within the service offering. The vulvodynia treatment market also includes sales of topical pain relief products, pregabalin, hydroxyzine, beta-blockers, atypical antipsychotics, and alprazolam. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vulvodynia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vulvodynia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for vulvodynia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vulvodynia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Vulvodynia Treatment Market Characteristics

3. Vulvodynia Treatment Market Trends And Strategies

4. Vulvodynia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Vulvodynia Treatment Growth Analysis And Strategic Analysis Framework

6. Vulvodynia Treatment Market Segmentation

7. Vulvodynia Treatment Market Regional And Country Analysis

8. Asia-Pacific Vulvodynia Treatment Market

9. China Vulvodynia Treatment Market

10. India Vulvodynia Treatment Market

11. Japan Vulvodynia Treatment Market

12. Australia Vulvodynia Treatment Market

13. Indonesia Vulvodynia Treatment Market

14. South Korea Vulvodynia Treatment Market

15. Western Europe Vulvodynia Treatment Market

16. UK Vulvodynia Treatment Market

17. Germany Vulvodynia Treatment Market

18. France Vulvodynia Treatment Market

19. Italy Vulvodynia Treatment Market

20. Spain Vulvodynia Treatment Market

21. Eastern Europe Vulvodynia Treatment Market

22. Russia Vulvodynia Treatment Market

23. North America Vulvodynia Treatment Market

24. USA Vulvodynia Treatment Market

25. Canada Vulvodynia Treatment Market

26. South America Vulvodynia Treatment Market

27. Brazil Vulvodynia Treatment Market

28. Middle East Vulvodynia Treatment Market

29. Africa Vulvodynia Treatment Market

30. Vulvodynia Treatment Market Competitive Landscape And Company Profiles

31. Vulvodynia Treatment Market Other Major And Innovative Companies

32. Global Vulvodynia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vulvodynia Treatment Market

34. Recent Developments In The Vulvodynia Treatment Market

35. Vulvodynia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â